AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01139-07v1
52/5/1850    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Spanjaard, L.
Right arrow Articles by Vandenbroucke-Grauls, C. M. J. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spanjaard, L.
Right arrow Articles by Vandenbroucke-Grauls, C. M. J. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2008, p. 1850-1851, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01139-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Activity of Daptomycin against Listeria monocytogenes Isolates from Cerebrospinal Fluid{triangledown}

Lodewijk Spanjaard* and Christina M. J. E. Vandenbroucke-Grauls{dagger}

Netherlands Reference Laboratory for Bacterial Meningitis, Department of Medical Microbiology, and Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Received 29 August 2007/ Returned for modification 20 November 2007/ Accepted 13 February 2008


   ABSTRACT
Top
 ABSTRACT
TEXT
 REFERENCES
 
We tested the activity of daptomycin against 76 Listeria monocytogenes isolates from cerebrospinal fluid by broth dilution and Etest methods. For the broth dilution method, the MIC range was 1.0 to 8.0 and the MIC at which 90% of the isolates tested were inhibited (MIC90) was 4.0 mg/liter. For the Etest method, the MIC range was 1.0 to 4.0 and the MIC90 was 4.0 mg/liter. Presently, daptomycin cannot be recommended for the treatment of L. monocytogenes meningitis.


   TEXT
Top
 ABSTRACT
 TEXT
REFERENCES
 
Listeria monocytogenes is the second or third most frequently isolated gram-positive microorganism from patients with meningitis (12, 18). L. monocytogenes is always penicillin sensitive, thus, ampicillin or amoxicillin is the agent of first choice to treat Listeria meningitis (18). For patients allergic to penicillin, trimethoprim-sulfamethoxazole and, possibly, meropenem are alternatives. The results of treatment with vancomycin are disappointing (18).

Daptomycin is a lipopeptide antimicrobial agent with bactericidal activity against gram-positive microorganisms (6, 9, 10, 11, 13, 16, 17). We tested the daptomycin susceptibility of 76 L. monocytogenes isolates from meningitis patients in The Netherlands to investigate whether daptomycin is an alternative treatment for Listeria meningitis.

The Netherlands Reference Laboratory for Bacterial Meningitis receives about 80% of all cerebrospinal fluid (CSF) isolates in The Netherlands (12, 15). All 76 L. monocytogenes CSF isolates, each representing one patient and received during 2001 to 2005, were used in this study (3).

Susceptibility tests were performed by broth dilution and Etest methods. Mueller-Hinton (MH) broth (Difco formulation; Becton Dickinson, Cockeysville, MD) with calcium (final concentration, 50 mg/liter) was used for broth dilution by following the procedure of the daptomycin manufacturer (Cubist Pharmaceuticals, Lexington, MA). The final inoculum in each well was 5 x 105 CFU/ml. Colony counts of positive control wells were performed. The microdilution panels were incubated at 35°C in ambient air for 16 to 20 h prior to the visual determination of MICs. The control strains Enterococcus faecalis ATCC 29212 and Staphylococcus aureus ATCC 29213 were included with each test.

The Etest was performed with MH II agar BBL plates (Becton Dickinson) both without blood, as described by Jorgensen and Crawford (10), and with 5% sheep blood according to the Etest procedure of the manufacturer (AB Biodisk, Solna, Sweden). The addition of calcium was unnecessary, because calcium is incorporated in the daptomycin Etest strip. MH plates alone and MH plates with blood were inoculated using a 0.5 and 1.0 McFarland density suspension, respectively, and were incubated at 35°C in ambient air for 16 to 20 h.

From 2001 to 2005, the annual number of L. monocytogenes CSF isolates recovered varied between 10 and 19. Among the 76 strains collected, 49% were serotype 4b and 42% were type 1/2a. The daptomycin MICs at which 50 and 90% of the tested isolates were inhibited (MIC50 and MIC90, respectively), as determined by broth dilution, were both 4.0 mg/liter (Table 1). For the Etest on plates without blood, the MIC50 and MIC90 were 2.0 and 4.0 mg/liter, respectively. For 26 (34%) of the 76 strains, the MIC determined by Etest was identical to that determined by broth dilution. For 39 (51%) strains, the MIC derived by the Etest method was a twofold-step lower than that derived from the broth method, and for 11 (14%) strains the MIC derived by the Etest method was two steps lower than the MIC determined by the broth method. The MIC by Etest was never higher than the MIC by broth dilution. For a random sample of 25 strains (33%), the Etest was performed on MH plates with blood. The results did not differ significantly from those for the Etest performed on plates without blood (Table 1). No daptomycin interpretative breakpoints have been established for Listeria. Therefore, it is not possible to analyze these data with respect to interpretative errors between the Etest and broth dilution as the reference method.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Daptomycin MICs for 76 Listeria monocytogenes CSF isolates determined by broth dilution and Etest methods

 
In this study, 76 L. monocytogenes isolates from patients with meningitis in The Netherlands from 2001 to 2005 were tested for daptomycin susceptibility. We performed broth dilution on samples in MH without blood, whereas the Clinical and Laboratory Standards Institute recommends using MH with 2.5 to 5% blood (1). L. monocytogenes is not truly fastidious, and testing with MH without blood has been done satisfactorily (8). Therefore, and because MICs by Etest derived from MH agar with and without blood did not show a significant difference from each other, we do not think that broth dilution performed with MH with blood would give results deviating from our present data. Listeria strains have been included in a few other daptomycin susceptibility studies (9, 11, 13, 17). However, a collection of CSF isolates as large as ours has not been tested before. Only one of the previous studies provided data about the Etest (9). Our broth dilution results were similar to those of Huang et al. and Streit et al. (9, 17) but were higher than those of Piper et al. (13). However, Piper et al. used a fivefold smaller inoculum, 105 CFU/ml. Our Etest results were similar to those of Huang et al. (9). However, we found that MICs determined by Etest were identical to or were a twofold step lower than those determined by broth dilution for 86% of the strains, and the MIC by Etest was never higher than the MIC by broth dilution. This is in contrast to the finding of Huang et al. that 35% of strains had a higher MIC by Etest than by broth dilution (9). Jorgensen and Crawford, who investigated enterococci, observed that daptomycin MICs determined by Etest tended to be lower than MICs determined by the dilution test (10). Because no breakpoints have been established for Listeria, it is not possible to analyze whether this would lead to interpretative errors with Etest.

The standard antimicrobial treatment of L. monocytogenes meningitis consists of ampicillin or amoxicillin. Only a few alternatives are available for patients allergic to penicillin (18). It is, therefore, essential that new antimicrobial agents be investigated with reference to their activity against meningitis pathogens. In animal studies of meningitis due to S. aureus (5, 7) and Streptococcus pneumoniae (2), daptomycin was more efficacious than vancomycin. However, daptomycin MICs for the S. aureus and S. pneumoniae strains used were 0.25 (7), 1.0 (5), and 0.06 (2), respectively, which are much lower than the daptomycin MIC50 for L. monocytogenes. Furthermore, vancomycin is not the standard therapy for Listeria meningitis. The efficacy of an antibiotic in meningitis also depends on the concentration attained in CSF. The average daptomycin peak concentration in volunteer plasma is about 60 mg/liter with the presently recommended dosing regimen (4 mg/kg of body weight once daily) (4). In the rabbit meningitis model, the daptomycin CSF concentration does not exceed 6% of the plasma concentration (2, 5). In plasma, daptomycin is 92% protein bound. Hence, the concentration of free drug in CSF will be relatively higher due to the lack of protein in the CSF. For the successful treatment of bacterial meningitis, the antimicrobial agent should exert a bactericidal effect (18). In a mouse model, the daptomycin peak concentration needs to be at least seven times the MIC to produce a bactericidal effect (14). If this applies to humans, it can be calculated that the daptomycin CSF concentration should be at least 25 mg/liter to effectively treat 90% of patients with Listeria meningitis.

The conclusion of this study is that daptomycin cannot be recommended for the treatment of L. monocytogenes meningitis until more data are available on the penetration of daptomycin in human CSF and the amount of free drug present in CSF.


   ACKNOWLEDGMENTS
 
A. Arends-van't Klooster and V. Godfried-Barbij are gratefully acknowledged for performing the susceptibility tests. Daptomycin powder and Etest strips were kindly provided by Cubist Pharmaceuticals.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Medical Microbiology, L1-243, Academic Medical Center, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands. Phone: 31 20 566 3026. Fax: 31 20 566 9745. E-mail: L.Spanjaard{at}amc.uva.nl Back

{triangledown} Published ahead of print on 19 February 2008. Back

{dagger} Present address: Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, The Netherlands. Back


   REFERENCES
Top
 ABSTRACT
 TEXT
 REFERENCES
 

  1. Clinical and Laboratory Standards Institute. 2006. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Approved standard M45-A. Clinical and Laboratory Standards Institute, Wayne, PA.
  2. Cottagnoud, P., M. Pfister, F. Acosta, M. Cottagnoud, L. Flatz, F. Kühn, H. P. Müller, and A. Stucki. 2004. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob. Agents Chemother. 48:3928-3933.[Abstract/Free Full Text]
  3. Doorduyn, Y., C. M. de Jager, W. K. van der Zwaluw, W. J. B. Wannet, A. van der Ende, L. Spanjaard, and Y. T. H. P. van Duynhoven. 2006. Invasive Listeria monocytogenes infections in the Netherlands, 1995-2003. Eur. J. Clin. Microbiol. Infect. Dis. 25:433-442.[CrossRef][Medline]
  4. Dvorchik, B. H., D. Brazier, M. F. DeBruin, and R. D. Arbeit. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323.[Abstract/Free Full Text]
  5. Gerber, P., A. Stucki, F. Acosta, M. Cottagnoud, and P. Cottagnoud. 2006. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J. Antimicrob. Chemother. 57:720-723.[Abstract/Free Full Text]
  6. Hancock, R. E. 2005. Mechanisms of action of newer antibiotics for gram-positive pathogens. Lancet Infect. Dis. 5:209-218.[CrossRef][Medline]
  7. Haworth, C. S., M. W. Sobieski, W. M. Scheld, and T. S. Park. 1990. Staphylococcus aureus ventriculitis treated with single-dose intraventricular vancomycin or daptomycin (LY146032): bacterial and antibiotic kinetics in hydrocephalic rabbits. Antimicrob. Agents Chemother. 34:245-251.[Abstract/Free Full Text]
  8. Hindler, J. F., and J. B. Patel. 2007. Susceptibility test methods: fastidious bacteria, p. 1193-1213. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed., vol. 1. ASM Press, Washington, DC.
  9. Huang, Y. T., C. H. Liao, L. J. Teng, and P. R. Hsueh. 2007. Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method. Antimicrob. Agents Chemother. 51:1570-1572.[Abstract/Free Full Text]
  10. Jorgensen, J. H., and S. A. Crawford. 2006. Assessment of two commercial susceptibility test methods for determination of daptomycin MICs. J. Clin. Microbiol. 44:2126-2129.[Abstract/Free Full Text]
  11. King, A., and I. Phillips. 2001. The in vitro activity of daptomycin against 514 gram-positive aerobic clinical isolates. J. Antimicrob. Chemother. 48:219-223.[Abstract/Free Full Text]
  12. Netherlands Reference Laboratory for Bacterial Meningitis. 2006. Bacterial meningitis in the Netherlands. Annual report 2005. University of Amsterdam, The Netherlands.
  13. Piper, K. E., J. M. Steckelberg, and R. Patel. 2005. In vitro activity of daptomycin against clinical isolates of gram-positive bacteria. J. Infect. Chemother. 11:207-209.[CrossRef][Medline]
  14. Safdar, N., D. Andes, and W. A. Craig. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63-68.[Abstract/Free Full Text]
  15. Spanjaard, L., P. Bol, W. Ekker, and H. C. Zanen. 1985. The incidence of bacterial meningitis in the Netherlands; a comparison of three registration systems, 1977-1982. J. Infect. 11:259-268.[CrossRef][Medline]
  16. Steenbergen, J. N., J. Alder, G. M. Thorne, and F. P. Tally. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. J. Antimicrob. Chemother. 55:283-288.[Abstract/Free Full Text]
  17. Streit, J. M., R. N. Jones, and H. S. Sader. 2004. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical gram-positive organisms. J. Antimicrob. Chemother. 53:669-674.[Abstract/Free Full Text]
  18. Tunkel, A. R., and W. M. Scheld. 2005. Acute meningitis, p. 1083-1126. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 6th ed., vol. 1. Elsevier, Philadelphia, PA.

Antimicrobial Agents and Chemotherapy, May 2008, p. 1850-1851, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01139-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01139-07v1
52/5/1850    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Spanjaard, L.
Right arrow Articles by Vandenbroucke-Grauls, C. M. J. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spanjaard, L.
Right arrow Articles by Vandenbroucke-Grauls, C. M. J. E.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS